Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment

Atsushi Kiba, Kouji Banno, Megumi Yanokura, Mari Asada, Yusuke Nakayama, Daisuke Aoki, Tatsuya Watanabe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim Leuprolide acetate, an analog of gonadotropin-releasing hormone (GnRH), regresses endometriotic tissue and reduces pain, resulting in clinical improvement upon treatment. The molecular mechanisms involved in the regression of endometriotic tissue, however, remain to be elucidated. In this study, we performed genome-wide gene expression profiling of clinical specimens of ovarian endometrioma to obtain insight into the effects of leuprolide acetate treatment. Methods We obtained clinical samples from nine normal eutopic endometrium tissues, eight ovarian endometriotic tissues, and 12 leuprolide acetate-treated endometriotic tissues. We compared the gene expression profiles of the three groups using Affymetrix GeneChip Human genome arrays and bioinformatic analysis, including molecular concept analysis. Results Leuprolide acetate-treated endometriotic tissue showed downregulated genes associated with the biological functions of steroid hormone regulation, cell proliferation, inflammation, and intracellular signaling. These genes included PTGDS, GRP, APLP2, PLTP, and FGFRL1. In contrast, genes upregulated by leuprolide acetate treatment were associated with cell growth inhibition and apoptosis. These genes included CARD11 and USP18. Conclusions These preliminary results based on GeneChip analysis suggest that leuprolide acetate treatment induces a modulation of gene expression that allows for cooperative alterations in disease state. This study gives new insight into the effects of leuprolide acetate treatment. Further investigations with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry are needed to validate this study and to explore new therapeutic targets and biomarkers of endometriosis.

Original languageEnglish
Pages (from-to)1598-1606
Number of pages9
JournalJournal of Obstetrics and Gynaecology Research
Volume41
Issue number10
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Leuprolide
Messenger RNA
Endometriosis
Therapeutics
Genes
Nociceptive Pain
Gene Expression Profiling
Human Genome
Endometrium
Computational Biology
Transcriptome
Gonadotropin-Releasing Hormone
Reverse Transcription
Down-Regulation
Biomarkers
Immunohistochemistry
Steroids
Cell Proliferation
Genome
Hormones

Keywords

  • endometriosis
  • geneChip
  • leuprolide acetate

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment. / Kiba, Atsushi; Banno, Kouji; Yanokura, Megumi; Asada, Mari; Nakayama, Yusuke; Aoki, Daisuke; Watanabe, Tatsuya.

In: Journal of Obstetrics and Gynaecology Research, Vol. 41, No. 10, 01.10.2015, p. 1598-1606.

Research output: Contribution to journalArticle

Kiba, Atsushi ; Banno, Kouji ; Yanokura, Megumi ; Asada, Mari ; Nakayama, Yusuke ; Aoki, Daisuke ; Watanabe, Tatsuya. / Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment. In: Journal of Obstetrics and Gynaecology Research. 2015 ; Vol. 41, No. 10. pp. 1598-1606.
@article{4432b4407db144a09638aa1fa5e5a727,
title = "Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment",
abstract = "Aim Leuprolide acetate, an analog of gonadotropin-releasing hormone (GnRH), regresses endometriotic tissue and reduces pain, resulting in clinical improvement upon treatment. The molecular mechanisms involved in the regression of endometriotic tissue, however, remain to be elucidated. In this study, we performed genome-wide gene expression profiling of clinical specimens of ovarian endometrioma to obtain insight into the effects of leuprolide acetate treatment. Methods We obtained clinical samples from nine normal eutopic endometrium tissues, eight ovarian endometriotic tissues, and 12 leuprolide acetate-treated endometriotic tissues. We compared the gene expression profiles of the three groups using Affymetrix GeneChip Human genome arrays and bioinformatic analysis, including molecular concept analysis. Results Leuprolide acetate-treated endometriotic tissue showed downregulated genes associated with the biological functions of steroid hormone regulation, cell proliferation, inflammation, and intracellular signaling. These genes included PTGDS, GRP, APLP2, PLTP, and FGFRL1. In contrast, genes upregulated by leuprolide acetate treatment were associated with cell growth inhibition and apoptosis. These genes included CARD11 and USP18. Conclusions These preliminary results based on GeneChip analysis suggest that leuprolide acetate treatment induces a modulation of gene expression that allows for cooperative alterations in disease state. This study gives new insight into the effects of leuprolide acetate treatment. Further investigations with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry are needed to validate this study and to explore new therapeutic targets and biomarkers of endometriosis.",
keywords = "endometriosis, geneChip, leuprolide acetate",
author = "Atsushi Kiba and Kouji Banno and Megumi Yanokura and Mari Asada and Yusuke Nakayama and Daisuke Aoki and Tatsuya Watanabe",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/jog.12768",
language = "English",
volume = "41",
pages = "1598--1606",
journal = "Asia-Oceania Journal of Obstetrics and Gynaecology",
issn = "1341-8076",
publisher = "Blackwell Publishing Asia",
number = "10",

}

TY - JOUR

T1 - Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment

AU - Kiba, Atsushi

AU - Banno, Kouji

AU - Yanokura, Megumi

AU - Asada, Mari

AU - Nakayama, Yusuke

AU - Aoki, Daisuke

AU - Watanabe, Tatsuya

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Aim Leuprolide acetate, an analog of gonadotropin-releasing hormone (GnRH), regresses endometriotic tissue and reduces pain, resulting in clinical improvement upon treatment. The molecular mechanisms involved in the regression of endometriotic tissue, however, remain to be elucidated. In this study, we performed genome-wide gene expression profiling of clinical specimens of ovarian endometrioma to obtain insight into the effects of leuprolide acetate treatment. Methods We obtained clinical samples from nine normal eutopic endometrium tissues, eight ovarian endometriotic tissues, and 12 leuprolide acetate-treated endometriotic tissues. We compared the gene expression profiles of the three groups using Affymetrix GeneChip Human genome arrays and bioinformatic analysis, including molecular concept analysis. Results Leuprolide acetate-treated endometriotic tissue showed downregulated genes associated with the biological functions of steroid hormone regulation, cell proliferation, inflammation, and intracellular signaling. These genes included PTGDS, GRP, APLP2, PLTP, and FGFRL1. In contrast, genes upregulated by leuprolide acetate treatment were associated with cell growth inhibition and apoptosis. These genes included CARD11 and USP18. Conclusions These preliminary results based on GeneChip analysis suggest that leuprolide acetate treatment induces a modulation of gene expression that allows for cooperative alterations in disease state. This study gives new insight into the effects of leuprolide acetate treatment. Further investigations with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry are needed to validate this study and to explore new therapeutic targets and biomarkers of endometriosis.

AB - Aim Leuprolide acetate, an analog of gonadotropin-releasing hormone (GnRH), regresses endometriotic tissue and reduces pain, resulting in clinical improvement upon treatment. The molecular mechanisms involved in the regression of endometriotic tissue, however, remain to be elucidated. In this study, we performed genome-wide gene expression profiling of clinical specimens of ovarian endometrioma to obtain insight into the effects of leuprolide acetate treatment. Methods We obtained clinical samples from nine normal eutopic endometrium tissues, eight ovarian endometriotic tissues, and 12 leuprolide acetate-treated endometriotic tissues. We compared the gene expression profiles of the three groups using Affymetrix GeneChip Human genome arrays and bioinformatic analysis, including molecular concept analysis. Results Leuprolide acetate-treated endometriotic tissue showed downregulated genes associated with the biological functions of steroid hormone regulation, cell proliferation, inflammation, and intracellular signaling. These genes included PTGDS, GRP, APLP2, PLTP, and FGFRL1. In contrast, genes upregulated by leuprolide acetate treatment were associated with cell growth inhibition and apoptosis. These genes included CARD11 and USP18. Conclusions These preliminary results based on GeneChip analysis suggest that leuprolide acetate treatment induces a modulation of gene expression that allows for cooperative alterations in disease state. This study gives new insight into the effects of leuprolide acetate treatment. Further investigations with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry are needed to validate this study and to explore new therapeutic targets and biomarkers of endometriosis.

KW - endometriosis

KW - geneChip

KW - leuprolide acetate

UR - http://www.scopus.com/inward/record.url?scp=84943351539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943351539&partnerID=8YFLogxK

U2 - 10.1111/jog.12768

DO - 10.1111/jog.12768

M3 - Article

C2 - 26374406

AN - SCOPUS:84943351539

VL - 41

SP - 1598

EP - 1606

JO - Asia-Oceania Journal of Obstetrics and Gynaecology

JF - Asia-Oceania Journal of Obstetrics and Gynaecology

SN - 1341-8076

IS - 10

ER -